Replies to post #36424 on Biotech Values

[quantumdot]

Re: Tyzeka vs. Hespera

These data make me want to see a 4th arm; that is Telbivudine switching to Adefovir.

Just looking at the tail ends of the curves makes me think that the sprinter would be better followed by the marathoner than vice-versa.